Breaking News

Citius’ LYMPHIR Shows Potential to Boost Pembrolizumab Efficacy

Citius shares promising results from ongoing Phase I clinical trial evaluating KEYTRUDA in combination with LYMPHIR in patients with recurrent solid tumors.

Author Image

By: Charlie Sternberg

Associate Editor

Citius Pharmaceuticals Inc. and Citius Oncology Inc. have announced promising preliminary results from an ongoing investigator-initiated Phase I clinical trial evaluating the safety and efficacy of a combined regimen of pembrolizumab (KEYTRUDA) and LYMPHIR (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors.   The trial is being conducted by Haider Mahdi, M.D., Assistant Professor, Department of Obstetrics, Gynecology & Reproductive Sciences, at the University of Pi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters